Lidoflazine
From Wikipedia, the free encyclopedia
 |
|
|
Lidoflazine
|
|
| Systematic (IUPAC) name | |
| 2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide | |
| Identifiers | |
| CAS number | |
| ATC code | C08 |
| PubChem | |
| Chemical data | |
| Formula | C30H35F2N3O |
| Mol. mass | 491.615 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Lidoflazine is a piperazine calcium channel blocker. It is a coronary vasodilator with some antiarrhythmic action. Lidoflazine was discovered at Janssen Pharmaceutica in 1964.
[edit] References
- Schaper WK, Xhonneux R, Jageneau AH., Stimulation of the coronary collateral circulation by lidoflazine (R 7904), Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1965 Nov 4;252(1):1-8.
- Schaper WK, Xhoneux R, Jageneau AH, Janssen PA., The cardiovascular pharmacology of lidoflazine, a long-acting coronary vasodilator, J Pharmacol Exp Ther. 1966 May;152(2):265-74.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
